NEW YORK (GenomeWeb) – RNAi contract research firm Cenix Bioscience is shutting down, according to a statement on the company's website.
Cenix CEO and CSO Christopher Echeverri confirmed the situation, but declined to comment further.
The company was founded about 15 years ago to provide high-throughput target discovery and validation services for academic and industry partners, and also developed research products such as genome-wide siRNA libraries. The German company had also been exploring RNAi delivery technologies for in vivo applications, and in 2012 established a US subsidiary to help establish partnerships in North America.